GPhA Praises Bipartisan Bill To Prevent Use Of REMS To Delay Generics

The generic drug industry applauds a new bipartisan effort to stop innovator drug companies from using restrictive safety designations, known as REMS, to delay marketing of generic drugs and biosimilars. A bill introduced Thursday (Sept. 18) by Reps. Steve Stivers (R-OH) and Rep. Peter Welch (D-VT) would prevent drug companies from creating any distribution or sales condition that would prevent their drugs from being used by generic or biosimilar makers for development and testing purposes. The generic drug trade lobby,...